GLOBAL immunology company Argenx and Monash University have formed a strategic partnership to advance a pioneering molecule for autoimmune diseases as part of Argenx's Immunology Innovation Program.
The partners are collaborating to advance an antibody molecule in pre-clinical development, with the shared ambition of one day addressing diseases with significant unmet need for patients.
"Australia has built a world-class environment for innovative research," said Argenx Australia general manager Kathryn Evans.
"This collaboration with Monash University reflects our continued interest in engaging deeply with Australia's research community and learning from the scientific rigour and creativity that exists here," Evans enthused.
This is Monash's first partnership with Argenx and, after signing with UniSA last year, the second R&D partnership for Argenx in Australia (PD 15 Oct 2025).
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jan 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jan 26
